Skip to main content
. 2019 Mar 22;11(3):405. doi: 10.3390/cancers11030405

Table 1.

Baseline patient characteristics.

Variable n = 125
Age (years, range) 74.3 ± 8.86 (41–88)
Gender (Male vs. Female) 96/29
Child-Pugh score (score of 5 vs. score of 6) 69/56
Etiology (HBV vs. HCV vs. non-B non-C) 12/64/49
Treatment history (Naïve vs. recurrence) 30/95
Up-to-seven criteria (within vs. beyond) 68/57
Tumor number 4.47 ± 3.67
Maximum tumor size (cm) 4.86 ± 9.45
Number of TACE procedures 1.95 ± 1.23
AST (IU/L) 47.8 ± 30.5
ALT (IU/L) 35.1 ± 30.3
Platelets (×104/μL) 14.8 ± 9.92
ALB (g/dL) 3.68 ± 0.43
T-Bil (mg/dL) 0.82 ± 0.31
PT (%) 90.5 ± 14.8
AFP (ng/mL) 3506 ± 14194
DCP (mAU/mL) 2900 ± 9532
FIB-4 index 5.59 ± 4.00
M2BPGi (cut-off index) 3.31 ± 3.01

Values are presented as mean ± standard deviation (range) or number. Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; TACE, transarterial chemoembolization; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALB, albumin; T-Bil, total bilirubin; PT, prothrombin time; AFP, α–fetoprotein; DCP, des-γ-carboxy prothrombin; FIB-4, Fibrosis-4; M2BPGi, Mac-2-binding protein glycosylation isomer.